After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

The landmark discoveries of leptin and adiponectin firmly established adipose tissue as a
sophisticated and highly active endocrine organ, opening a new era of investigating adipose …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for
treatment of diabetes, have been shown to possess a favorable metabolic profile and to …

Background: Sodium-glucose cotransporter-2 inhibitors improve heart failure–related
outcomes. The mechanisms underlying these benefits are not well understood, but diuretic …

Background Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce hospitalizations
and death from heart failure (HF), but their effect on arrhythmia expression has been poorly …

There is a close relationship between diabetes mellitus and heart failure, and diabetes is an
independent risk factor for heart failure. Diabetes and heart failure are linked by not only the …

The burden of diabetic cardiovascular autonomic neuropathy (CAN) is expected to increase
due to the diabetes epidemic and its early and widespread appearance. CAN has a definite …

Background Protection from lethal ventricular arrhythmias leading to sudden cardiac death
(SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic …

Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose
cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic …